Session Track · IDC 2027

Malignant Melanoma at IDC 2027

Part of the IDC 2027 scientific program · NH Villa Carpegna, Rome, Italy · June 21–23, 2027

About the Malignant Melanoma Session

Malignant melanoma is considered one of the most serious forms of skin cancer. Melanoma is a type of cancer that begins in the skin cells that produce melanin, which is a pigment that gives skin its color. When these cells, called melanocytes, grow uncontrollably, they can form a mass of cancer cells that can invade other nearby organs and spread to distant parts of the body. The most common type of melanoma is called cutaneous melanoma, and it is typically seen on areas of skin that are exposed to the sun, but can occur anywhere on the body. People with lighter skin complexions, especially those with red or blond hair and blue eyes, are at greatest risk. Signs of the disease may include a change in the size, shape, color, or texture of a mole, or the appearance of a new lessee or wart-like spot on the skin, commonly referred to as an "ugly duckling." Early diagnosis of malignant melanoma is critical, as treatment can be more effective when caught in its early stages. Treatments for melanoma can include surgery, chemotherapy, or immunotherapy, and can depend on the stage of the cancer and individual health. Malignant melanoma is a life-threatening disease and must be taken seriously. Anyone with any suspicious lesions or spots on their skin should seek medical attention and get them properly examined. Early diagnosis of malignant melanoma increases chances of effective treatment.

Featured Speakers — Malignant Melanoma 2027

Speaker lineup for this track will be announced soon.

Browse all speakers →

Recent Research Presented at Malignant Melanoma Sessions

Selected abstracts from this track will be published here.

Related Scientific Sessions at IDC 2027

Why Attend the Malignant Melanoma Conference 2027

Present Your Research

Oral and poster slots for original Malignant Melanoma work, reviewed by the scientific committee.

Network Globally

Meet researchers, clinicians, and industry leaders from around the world across three days.

Publish & Get Indexed

Accepted abstracts appear in the indexed conference proceedings with a citable DOI.

Learn from Keynotes

Plenary lectures from leading voices shaping Malignant Melanoma research and practice.

Hybrid Flexibility

Attend in person in Rome or join virtually — same program, same certificate.

Join IDC 2027 for the Malignant Melanoma track

Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.

Malignant Melanoma Conference 2027 — FAQs

What is the Malignant Melanoma track at IDC 2027?

The Malignant Melanoma track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Malignant Melanoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.

Who should attend the Malignant Melanoma sessions?

Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Malignant Melanoma are all welcome — whether presenting or attending.

Can I present my research in the Malignant Melanoma track?

Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.

Is virtual attendance available for Malignant Melanoma sessions?

Yes. IDC 2027 is a hybrid conference — attend the Malignant Melanoma track in person in Rome or join live online, with on-demand access afterward.

Join the IDC 2027 delegation

Rome · June 21–23, 2027 · Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.